Product image of Glucose 50% Labesfal (Glucose) supplied by GNH India

Glucose 50% Labesfal

Active Ingredient:
Glucose
Origin:
EU

Glucose 50% Labesfal (Glucose)

Glucose 50% Labesfal is an intravenous injection solution containing 50% w/v glucose as the active ingredient. Produced under the Labesfal brand, this sterile solution is supplied in a concentration suitable for rapid infusion. It is classified as an excipient rather than a therapeutic drug and is marketed in the European Union as a prescription‑only product for clinical use in various medical settings, including hospital procedures and emergency care.

Manufacturer / TM Owner

Labesfal Laboratorios Almiro, S.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Glucose 50% Labesfal is used primarily as an energy source and volume expander in clinical settings where rapid restoration of blood glucose levels or intravascular volume is required.

  • Management of hypoglycemia during surgery or anesthesia.
  • Provision of caloric support in patients unable to eat orally.
  • Dilution and carrier for intravenous drug admixtures.
  • Fluid resuscitation in trauma or shock when dextrose is indicated.
  • Support for metabolic testing or diagnostic procedures requiring glucose.

Side Effects

Adverse reactions to Glucose 50% Labesfal are generally related to the solution’s osmolarity and the patient’s underlying condition.

Common

  • Local irritation or pain at the infusion site.
  • Mild hyperglycemia if administered rapidly.
  • Nausea or vomiting related to high glucose load.
  • Electrolyte shifts, particularly low serum potassium.

Serious

  • Severe hyperglycemia leading to osmotic diuresis.
  • Phlebitis or thrombophlebitis at the catheter site.
  • Volume overload causing pulmonary edema.
  • Hypersensitivity reactions such as rash or anaphylaxis.

Precautions & Warnings

When using Glucose 50% Labesfal, clinicians should assess patient-specific factors and monitor for potential complications associated with high‑concentration dextrose solutions.

  • Verify blood glucose levels before and after infusion.
  • Adjust infusion rate in patients with renal or cardiac insufficiency.
  • Avoid use in patients with known hypersensitivity to glucose solutions.
  • Monitor serum electrolytes, especially potassium, during prolonged administration.
  • Use caution in neonates and infants due to immature metabolic pathways.
  • Ensure proper catheter placement to reduce risk of extravasation.

Avoid Interactions

Glucose 50% Labesfal may interact with other intravenous therapies or medications that affect glucose metabolism or fluid balance.

Avoid

  • Co‑administration with hypertonic saline solutions without proper dilution.
  • Simultaneous infusion of insulin without adjusting glucose delivery.

Use with caution

  • Concurrent use of diuretics that may exacerbate electrolyte disturbances.
  • Administration alongside catecholamines that can increase blood glucose levels.
  • Use with beta‑blockers, which may mask signs of hypoglycemia.
  • Combination with other carbohydrate‑containing fluids, risking hyperglycemia.

Frequently Asked Questions

Glucose 50% Labesfal contains glucose at a concentration of 50% weight/volume (w/v) in a sterile injection solution.

It is administered intravenously, typically through a peripheral or central venous catheter, according to the prescribing clinician’s instructions.

Use in neonates and infants should be done with caution, and dosing must be individualized by a qualified healthcare professional.

It is classified as an excipient, providing glucose as a source of energy and fluid volume rather than a therapeutic drug.

Common side effects include local irritation at the infusion site, mild hyperglycemia, nausea, vomiting, and transient electrolyte shifts.

It should be avoided when co‑administered with hypertonic saline without dilution or when insulin is infused simultaneously without adjusting glucose delivery.

Blood glucose, serum electrolytes (especially potassium), and fluid balance should be monitored regularly during and after infusion.

It can serve as a diluent for certain IV medications, but compatibility should be confirmed before mixing.

No, it is a prescription‑only product and must be prescribed by a licensed healthcare provider.

Infusion should be stopped immediately, and appropriate medical treatment for the reaction should be initiated.

Store in a controlled room temperature environment, protected from light, and keep the container sealed until use.

It is marketed in the European Union as a prescription‑only sterile injection solution complying with EU pharmaceutical regulations.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Glucose

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT